BIIB News and Press, Biogen Inc. From 02/14/24

2024-02-14 10:33:07 ET Read the full article on Seeking Alpha For further details see: DOJ issues subpoena for info on Biogen's foreign operations

2024-02-14 09:50:29 ET More on Biogen Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade) Biogen Inc. (BIIB) Q4 2023 Earnings Call Transcript Biogen Inc. 2023 Q4 - Results - Earnings Call Presentation Biogen slips as outlook disappo...

2024-02-14 02:55:38 ET Summary Q4 earnings underwhelmed, with misses on EPS and revenue; Leqembi and Zurzuvae's performances were particularly disappointing. Biogen's significant investments in Alzheimer's treatments, especially Leqembi, have yet to yield substantial returns. ...

2024-02-13 14:45:17 ET Image source: The Motley Fool. Biogen (NASDAQ: BIIB) Q4 2023 Earnings Call Feb 13, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Biogen (BIIB) Q4 2023 Earnings Call Transcript

2024-02-13 13:13:00 ET Summary The January headline CPI rose 0.3%; Core CPI up 0.4%. Coca-Cola reports strong Q4 results, Shopify just narrowly tops consensus. Citi says the benchmark index will close out 2024 at 5,100. Listen below or on the go on Apple Podcasts ...

2024-02-13 12:25:05 ET Biogen Inc. (BIIB) Q4 2023 Earnings Conference Call February 13, 2024 8:00 AM ET Company Participants Chuck Triano - Head of Investor Relations Chris Viehbacher - President and Chief Executive Officer Priya Singhal - Head of Development ...

2024-02-13 07:59:24 ET More on Biogen Biotech And Pharma Diversification Pays Off Biogen Inc. (BIIB) JPMorgan 42nd Annual Healthcare Conference (Transcript) Biogen: LEQEMBI's $10 Billion Potential Biogen misses top-line and bottom-line estimates; initiates FY...

2024-02-13 07:18:36 ET More on Biogen Biotech And Pharma Diversification Pays Off Biogen: LEQEMBI's $10 Billion Potential Biogen gets EU approval for Friedrich's ataxia drug Read the full article on Seeking Alpha For further details see: Biogen mi...

ESSA Pharma Inc. (EPIX) is expected to report $-0.17 for Q1 2024 QuidelOrtho Corp Com (QDEL) is expected to report $2.01 for Q4 2023 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 Portsmouth Square, Inc. (PRSI) is expected to report for Q2 2024 Similarweb Ltd. (SMWB) ...

2024-02-13 00:39:21 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...